| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 105 | 2024 | 5566 | 7.700 |
Why?
|
| Lung Neoplasms | 131 | 2024 | 12019 | 6.190 |
Why?
|
| Proton Therapy | 40 | 2024 | 1635 | 5.320 |
Why?
|
| Radiation Pneumonitis | 26 | 2018 | 313 | 5.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 39 | 2023 | 2161 | 4.100 |
Why?
|
| Chemoradiotherapy | 35 | 2022 | 2027 | 3.310 |
Why?
|
| Esophageal Neoplasms | 37 | 2024 | 3234 | 2.210 |
Why?
|
| Radiotherapy, Conformal | 17 | 2020 | 898 | 2.200 |
Why?
|
| Esophagitis | 17 | 2020 | 201 | 1.640 |
Why?
|
| Radiation Injuries | 24 | 2022 | 1469 | 1.630 |
Why?
|
| Radiotherapy Dosage | 44 | 2023 | 3999 | 1.480 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 29 | 2023 | 2450 | 1.310 |
Why?
|
| Lung | 21 | 2022 | 3288 | 1.270 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2018 | 125 | 1.160 |
Why?
|
| Organs at Risk | 14 | 2023 | 558 | 1.150 |
Why?
|
| Aged, 80 and over | 79 | 2024 | 30923 | 1.080 |
Why?
|
| Heart | 13 | 2023 | 1159 | 1.080 |
Why?
|
| Thoracic Neoplasms | 6 | 2020 | 352 | 1.040 |
Why?
|
| Aged | 122 | 2024 | 73127 | 1.040 |
Why?
|
| Radiotherapy, Image-Guided | 6 | 2017 | 340 | 1.010 |
Why?
|
| Tumor Burden | 15 | 2018 | 2031 | 0.970 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2017 | 4646 | 0.970 |
Why?
|
| Middle Aged | 122 | 2024 | 90030 | 0.930 |
Why?
|
| Small Cell Lung Carcinoma | 5 | 2023 | 417 | 0.910 |
Why?
|
| Radiosurgery | 14 | 2021 | 1383 | 0.880 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2012 | 38 | 0.840 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2013 | 33 | 0.820 |
Why?
|
| Humans | 192 | 2024 | 270033 | 0.810 |
Why?
|
| Male | 130 | 2024 | 127917 | 0.800 |
Why?
|
| Female | 135 | 2024 | 148486 | 0.750 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2019 | 533 | 0.720 |
Why?
|
| Retrospective Studies | 71 | 2024 | 39736 | 0.700 |
Why?
|
| Pericardial Effusion | 2 | 2020 | 122 | 0.700 |
Why?
|
| Adult | 90 | 2023 | 81689 | 0.690 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2020 | 10382 | 0.670 |
Why?
|
| Re-Irradiation | 2 | 2017 | 166 | 0.650 |
Why?
|
| Esophagus | 7 | 2017 | 548 | 0.630 |
Why?
|
| Fatigue | 4 | 2019 | 1278 | 0.620 |
Why?
|
| Hepcidins | 1 | 2018 | 35 | 0.610 |
Why?
|
| Four-Dimensional Computed Tomography | 10 | 2023 | 231 | 0.610 |
Why?
|
| Minocycline | 1 | 2019 | 189 | 0.600 |
Why?
|
| Proportional Hazards Models | 17 | 2021 | 5099 | 0.600 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 405 | 0.590 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2017 | 103 | 0.570 |
Why?
|
| Smad4 Protein | 1 | 2018 | 201 | 0.560 |
Why?
|
| Neoplasm Staging | 42 | 2023 | 13996 | 0.550 |
Why?
|
| Adenocarcinoma | 22 | 2018 | 7883 | 0.530 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2015 | 41 | 0.520 |
Why?
|
| Nomograms | 1 | 2018 | 312 | 0.520 |
Why?
|
| Risk | 7 | 2018 | 1937 | 0.510 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 624 | 0.510 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2011 | 366 | 0.510 |
Why?
|
| Analysis of Variance | 11 | 2017 | 2316 | 0.510 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 698 | 0.510 |
Why?
|
| Combined Modality Therapy | 27 | 2020 | 9040 | 0.510 |
Why?
|
| Pneumonectomy | 6 | 2021 | 862 | 0.500 |
Why?
|
| Cyclooxygenase Inhibitors | 3 | 2005 | 177 | 0.490 |
Why?
|
| Cost of Illness | 2 | 2016 | 503 | 0.490 |
Why?
|
| Amphibian Venoms | 2 | 2011 | 12 | 0.470 |
Why?
|
| Photons | 4 | 2018 | 536 | 0.470 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2012 | 198 | 0.470 |
Why?
|
| Tomography, X-Ray Computed | 19 | 2020 | 7779 | 0.460 |
Why?
|
| Prospective Studies | 19 | 2024 | 13378 | 0.460 |
Why?
|
| Bayes Theorem | 5 | 2018 | 1058 | 0.450 |
Why?
|
| Protons | 7 | 2020 | 481 | 0.440 |
Why?
|
| Propensity Score | 3 | 2015 | 768 | 0.440 |
Why?
|
| Carcinoma, Squamous Cell | 16 | 2020 | 5585 | 0.430 |
Why?
|
| Treatment Outcome | 39 | 2024 | 33691 | 0.420 |
Why?
|
| Peptide Fragments | 1 | 2018 | 1305 | 0.410 |
Why?
|
| Lymph Nodes | 4 | 2018 | 3070 | 0.380 |
Why?
|
| Isoenzymes | 2 | 2004 | 650 | 0.380 |
Why?
|
| Pneumonia | 5 | 2024 | 795 | 0.380 |
Why?
|
| Quality of Life | 11 | 2020 | 4772 | 0.380 |
Why?
|
| Genotype | 8 | 2015 | 4249 | 0.380 |
Why?
|
| Follow-Up Studies | 24 | 2024 | 15172 | 0.380 |
Why?
|
| Yoga | 3 | 2019 | 88 | 0.360 |
Why?
|
| Organ Sparing Treatments | 3 | 2019 | 283 | 0.350 |
Why?
|
| Movement | 7 | 2014 | 562 | 0.340 |
Why?
|
| Treatment Failure | 10 | 2018 | 1425 | 0.340 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 637 | 0.340 |
Why?
|
| Smoking | 2 | 2018 | 2548 | 0.340 |
Why?
|
| Mindfulness | 2 | 2020 | 56 | 0.340 |
Why?
|
| Cyclooxygenase 2 | 3 | 2007 | 494 | 0.330 |
Why?
|
| Chemoradiotherapy, Adjuvant | 4 | 2019 | 562 | 0.330 |
Why?
|
| Incidence | 8 | 2020 | 5806 | 0.330 |
Why?
|
| Induction Chemotherapy | 5 | 2017 | 670 | 0.330 |
Why?
|
| Models, Statistical | 2 | 2012 | 1185 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 1469 | 0.320 |
Why?
|
| Radiation Dosage | 5 | 2020 | 1042 | 0.320 |
Why?
|
| Lymphopenia | 3 | 2023 | 211 | 0.320 |
Why?
|
| Prognosis | 21 | 2020 | 22451 | 0.310 |
Why?
|
| Survival Rate | 17 | 2024 | 12508 | 0.310 |
Why?
|
| Respiration | 6 | 2014 | 464 | 0.310 |
Why?
|
| Caregivers | 5 | 2020 | 752 | 0.310 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 3842 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 19 | 2020 | 16640 | 0.300 |
Why?
|
| Disease-Free Survival | 21 | 2017 | 10258 | 0.300 |
Why?
|
| Haplotypes | 1 | 2010 | 910 | 0.300 |
Why?
|
| Regression Analysis | 7 | 2018 | 1568 | 0.290 |
Why?
|
| Sulfonamides | 3 | 2012 | 1933 | 0.290 |
Why?
|
| Radiotherapy | 8 | 2018 | 1858 | 0.290 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2022 | 1688 | 0.280 |
Why?
|
| Risk Factors | 15 | 2018 | 17824 | 0.280 |
Why?
|
| Postoperative Care | 3 | 2021 | 728 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 3161 | 0.280 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2004 | 230 | 0.280 |
Why?
|
| Random Allocation | 2 | 2018 | 740 | 0.270 |
Why?
|
| Positron-Emission Tomography | 8 | 2020 | 2196 | 0.270 |
Why?
|
| Antineoplastic Agents | 12 | 2017 | 14615 | 0.260 |
Why?
|
| Thymidylate Synthase | 1 | 2005 | 57 | 0.260 |
Why?
|
| Carboplatin | 3 | 2018 | 879 | 0.260 |
Why?
|
| Survival Analysis | 11 | 2018 | 9288 | 0.250 |
Why?
|
| Respiratory Mechanics | 4 | 2020 | 175 | 0.250 |
Why?
|
| Area Under Curve | 2 | 2019 | 729 | 0.250 |
Why?
|
| Betacoronavirus | 2 | 2020 | 513 | 0.250 |
Why?
|
| Odds Ratio | 5 | 2018 | 2296 | 0.240 |
Why?
|
| Workflow | 2 | 2024 | 277 | 0.240 |
Why?
|
| Esophagectomy | 7 | 2018 | 946 | 0.240 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 1557 | 0.240 |
Why?
|
| 3' Untranslated Regions | 1 | 2005 | 340 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2010 | 1577 | 0.230 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2020 | 1260 | 0.220 |
Why?
|
| Patient Selection | 3 | 2020 | 2026 | 0.220 |
Why?
|
| Pyrazoles | 3 | 2012 | 1539 | 0.220 |
Why?
|
| Mesothelioma | 3 | 2015 | 558 | 0.220 |
Why?
|
| Spouses | 3 | 2020 | 140 | 0.220 |
Why?
|
| Artifacts | 2 | 2020 | 536 | 0.210 |
Why?
|
| Reproducibility of Results | 8 | 2018 | 6182 | 0.210 |
Why?
|
| Neoplasms | 7 | 2022 | 15902 | 0.210 |
Why?
|
| Risk Assessment | 8 | 2018 | 6752 | 0.210 |
Why?
|
| Radiation Oncology | 3 | 2024 | 558 | 0.200 |
Why?
|
| Carbon Monoxide | 2 | 2012 | 68 | 0.200 |
Why?
|
| Time Factors | 14 | 2021 | 12953 | 0.200 |
Why?
|
| Algorithms | 8 | 2022 | 3896 | 0.200 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 4318 | 0.200 |
Why?
|
| Disease Progression | 7 | 2017 | 6840 | 0.190 |
Why?
|
| Paclitaxel | 3 | 2018 | 2101 | 0.190 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10695 | 0.190 |
Why?
|
| Hodgkin Disease | 2 | 2001 | 1485 | 0.190 |
Why?
|
| Brain Neoplasms | 4 | 2017 | 4955 | 0.190 |
Why?
|
| China | 2 | 2020 | 634 | 0.190 |
Why?
|
| Molecular Chaperones | 2 | 2013 | 266 | 0.190 |
Why?
|
| Outpatients | 1 | 2024 | 460 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 6254 | 0.180 |
Why?
|
| Heat-Shock Proteins | 2 | 2013 | 330 | 0.180 |
Why?
|
| Spain | 1 | 2020 | 100 | 0.180 |
Why?
|
| France | 1 | 2020 | 120 | 0.180 |
Why?
|
| Dyspnea | 2 | 2022 | 420 | 0.180 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2021 | 211 | 0.180 |
Why?
|
| Italy | 1 | 2020 | 186 | 0.170 |
Why?
|
| Radiometry | 4 | 2018 | 1017 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 6 | 2019 | 5225 | 0.170 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 58 | 0.170 |
Why?
|
| Insurance Coverage | 2 | 2020 | 274 | 0.170 |
Why?
|
| Depression | 3 | 2019 | 1731 | 0.170 |
Why?
|
| Karnofsky Performance Status | 3 | 2017 | 174 | 0.160 |
Why?
|
| Radiation Oncologists | 1 | 2019 | 32 | 0.160 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2016 | 382 | 0.160 |
Why?
|
| Texas | 7 | 2021 | 6430 | 0.160 |
Why?
|
| Community Health Centers | 1 | 2019 | 50 | 0.160 |
Why?
|
| Relative Biological Effectiveness | 2 | 2017 | 227 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 73 | 0.160 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2018 | 67 | 0.150 |
Why?
|
| Time-to-Treatment | 2 | 2018 | 307 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 483 | 0.150 |
Why?
|
| Uncertainty | 3 | 2015 | 326 | 0.150 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 4944 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 7 | 2017 | 751 | 0.150 |
Why?
|
| Metastasectomy | 1 | 2020 | 209 | 0.150 |
Why?
|
| Mind-Body Therapies | 1 | 2017 | 29 | 0.150 |
Why?
|
| Genetic Variation | 2 | 2018 | 2165 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2022 | 2586 | 0.150 |
Why?
|
| Scattering, Radiation | 1 | 2018 | 334 | 0.150 |
Why?
|
| Endpoint Determination | 1 | 2018 | 179 | 0.140 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2000 | 320 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2020 | 880 | 0.140 |
Why?
|
| Medicaid | 1 | 2020 | 305 | 0.140 |
Why?
|
| Pleural Neoplasms | 2 | 2014 | 485 | 0.140 |
Why?
|
| Celecoxib | 3 | 2012 | 198 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 92 | 0.140 |
Why?
|
| Forecasting | 1 | 2019 | 699 | 0.140 |
Why?
|
| Young Adult | 11 | 2021 | 22134 | 0.140 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2018 | 583 | 0.130 |
Why?
|
| Logistic Models | 3 | 2020 | 3438 | 0.130 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 275 | 0.130 |
Why?
|
| Steroids | 1 | 2018 | 370 | 0.130 |
Why?
|
| Cardiovascular Diseases | 2 | 2022 | 2209 | 0.130 |
Why?
|
| Radiopharmaceuticals | 3 | 2016 | 1341 | 0.130 |
Why?
|
| Magnetic Fields | 1 | 2015 | 33 | 0.130 |
Why?
|
| Head and Neck Neoplasms | 3 | 2020 | 4139 | 0.130 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 637 | 0.130 |
Why?
|
| Precision Medicine | 2 | 2013 | 1207 | 0.120 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1995 | 80 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2020 | 9464 | 0.120 |
Why?
|
| ROC Curve | 1 | 2018 | 1248 | 0.120 |
Why?
|
| Survivors | 2 | 2017 | 1022 | 0.120 |
Why?
|
| Acute-Phase Reaction | 1 | 2014 | 24 | 0.120 |
Why?
|
| Lymphatic Metastasis | 4 | 2018 | 4956 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2015 | 550 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 2646 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1603 | 0.110 |
Why?
|
| Cancer Pain | 1 | 2019 | 344 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 3993 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2019 | 1272 | 0.110 |
Why?
|
| Pleura | 1 | 2014 | 130 | 0.110 |
Why?
|
| Fluorouracil | 4 | 2013 | 1989 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 3398 | 0.110 |
Why?
|
| Immune Tolerance | 1 | 2015 | 423 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 1309 | 0.110 |
Why?
|
| Esophagogastric Junction | 2 | 2015 | 553 | 0.110 |
Why?
|
| Mutation | 4 | 2024 | 15900 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 2056 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 2 | 2018 | 1387 | 0.110 |
Why?
|
| Inflammation | 2 | 2014 | 2491 | 0.110 |
Why?
|
| Lung Diseases | 2 | 2015 | 751 | 0.100 |
Why?
|
| Cytokines | 2 | 2019 | 2810 | 0.100 |
Why?
|
| Feasibility Studies | 5 | 2018 | 2358 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2014 | 724 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 2 | 2010 | 98 | 0.100 |
Why?
|
| Forced Expiratory Volume | 2 | 2012 | 327 | 0.100 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 704 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 862 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2012 | 71 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 27 | 0.100 |
Why?
|
| Vital Capacity | 1 | 2012 | 140 | 0.100 |
Why?
|
| Spinal Cord | 3 | 2012 | 721 | 0.100 |
Why?
|
| Self Report | 1 | 2016 | 795 | 0.100 |
Why?
|
| Gamma Rays | 1 | 2012 | 237 | 0.100 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 527 | 0.100 |
Why?
|
| Cardiac Glycosides | 1 | 2011 | 15 | 0.100 |
Why?
|
| Heart Diseases | 2 | 2014 | 718 | 0.100 |
Why?
|
| Cancer Care Facilities | 2 | 2017 | 907 | 0.100 |
Why?
|
| Esophageal Stenosis | 1 | 2011 | 90 | 0.100 |
Why?
|
| DNA Ligases | 1 | 2011 | 67 | 0.090 |
Why?
|
| Mice, Inbred C3H | 4 | 2012 | 403 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2014 | 261 | 0.090 |
Why?
|
| Palliative Care | 2 | 2020 | 2173 | 0.090 |
Why?
|
| Cranial Irradiation | 1 | 2013 | 322 | 0.090 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 354 | 0.090 |
Why?
|
| Mediastinal Neoplasms | 1 | 2014 | 427 | 0.090 |
Why?
|
| Liver Neoplasms | 3 | 2020 | 4814 | 0.090 |
Why?
|
| Pilot Projects | 4 | 2020 | 2843 | 0.090 |
Why?
|
| Standard of Care | 1 | 2012 | 275 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2012 | 302 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 2011 | 175 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 138 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 5061 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2023 | 2376 | 0.090 |
Why?
|
| Electroacupuncture | 1 | 2010 | 33 | 0.090 |
Why?
|
| Ileus | 1 | 2010 | 30 | 0.090 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 1427 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2011 | 233 | 0.080 |
Why?
|
| Salvage Therapy | 4 | 2018 | 2122 | 0.080 |
Why?
|
| Cause of Death | 1 | 2012 | 778 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 16183 | 0.080 |
Why?
|
| Sarcoma | 1 | 2020 | 1836 | 0.080 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 2663 | 0.080 |
Why?
|
| Stomach Neoplasms | 2 | 2015 | 2256 | 0.080 |
Why?
|
| Heart Septal Defects | 1 | 2009 | 49 | 0.080 |
Why?
|
| Gases | 1 | 2008 | 39 | 0.080 |
Why?
|
| Postoperative Complications | 3 | 2013 | 5666 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2014 | 1145 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2015 | 908 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1012 | 0.080 |
Why?
|
| Spirituality | 2 | 2020 | 129 | 0.080 |
Why?
|
| Coronary Circulation | 1 | 2009 | 235 | 0.080 |
Why?
|
| Exhalation | 2 | 2020 | 61 | 0.080 |
Why?
|
| Colectomy | 1 | 2010 | 291 | 0.070 |
Why?
|
| Quinazolines | 1 | 2013 | 956 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2017 | 5773 | 0.070 |
Why?
|
| Pain | 1 | 2016 | 1697 | 0.070 |
Why?
|
| Prednisone | 2 | 2000 | 1031 | 0.070 |
Why?
|
| Radiography | 4 | 2012 | 1984 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1042 | 0.070 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 743 | 0.070 |
Why?
|
| Sleep Wake Disorders | 3 | 2017 | 373 | 0.070 |
Why?
|
| Diaphragm | 1 | 2008 | 187 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 1708 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2007 | 82 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 1564 | 0.070 |
Why?
|
| Cisplatin | 3 | 2017 | 2497 | 0.070 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 619 | 0.070 |
Why?
|
| Probability | 2 | 2020 | 883 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1821 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2073 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2004 | 1742 | 0.070 |
Why?
|
| Vincristine | 2 | 2000 | 1581 | 0.070 |
Why?
|
| Psychometrics | 1 | 2011 | 969 | 0.070 |
Why?
|
| Kidney | 1 | 1994 | 2110 | 0.060 |
Why?
|
| Stomach | 1 | 2008 | 366 | 0.060 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1957 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 400 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2024 | 3553 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 787 | 0.060 |
Why?
|
| Recurrence | 3 | 2023 | 4872 | 0.060 |
Why?
|
| United States | 6 | 2020 | 15776 | 0.060 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2005 | 84 | 0.060 |
Why?
|
| Image Enhancement | 1 | 2008 | 553 | 0.060 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 5153 | 0.060 |
Why?
|
| Remission Induction | 4 | 2017 | 3648 | 0.060 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 1199 | 0.060 |
Why?
|
| Stress, Psychological | 3 | 2017 | 1041 | 0.060 |
Why?
|
| Histones | 1 | 2011 | 1512 | 0.060 |
Why?
|
| Intestinal Neoplasms | 1 | 2005 | 199 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 982 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 545 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2004 | 2926 | 0.050 |
Why?
|
| DNA Damage | 1 | 2011 | 1981 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2000 | 3142 | 0.050 |
Why?
|
| Adolescent | 6 | 2023 | 32647 | 0.050 |
Why?
|
| Lymph Node Excision | 2 | 2021 | 2056 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 661 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2000 | 3242 | 0.050 |
Why?
|
| Lymphatic Irradiation | 2 | 2013 | 139 | 0.050 |
Why?
|
| Age Factors | 3 | 2017 | 5449 | 0.050 |
Why?
|
| Medicare | 2 | 2018 | 925 | 0.050 |
Why?
|
| Skin Diseases | 1 | 2005 | 366 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2008 | 1560 | 0.050 |
Why?
|
| Amifostine | 1 | 2002 | 99 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2014 | 2887 | 0.050 |
Why?
|
| Radiation-Protective Agents | 1 | 2002 | 129 | 0.050 |
Why?
|
| Organ Motion | 1 | 2020 | 4 | 0.050 |
Why?
|
| Comorbidity | 3 | 2015 | 2389 | 0.050 |
Why?
|
| Endosonography | 1 | 2004 | 551 | 0.050 |
Why?
|
| Carcinoma | 1 | 2012 | 2607 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 2020 | 62 | 0.050 |
Why?
|
| Cardiotoxicity | 1 | 2022 | 151 | 0.050 |
Why?
|
| Benchmarking | 1 | 2023 | 275 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 4360 | 0.040 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2019 | 36 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 2170 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2020 | 71 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 202 | 0.040 |
Why?
|
| Etoposide | 1 | 2002 | 905 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2020 | 2269 | 0.040 |
Why?
|
| DNA Fingerprinting | 1 | 2019 | 177 | 0.040 |
Why?
|
| Alleles | 2 | 2019 | 2590 | 0.040 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 1066 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 1347 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2020 | 2238 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 564 | 0.040 |
Why?
|
| Social Adjustment | 1 | 2019 | 114 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2003 | 1140 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2024 | 930 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1808 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 485 | 0.040 |
Why?
|
| Automation | 1 | 2017 | 153 | 0.040 |
Why?
|
| Watchful Waiting | 1 | 2019 | 293 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2003 | 1496 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 1507 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2017 | 103 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 894 | 0.040 |
Why?
|
| Laparotomy | 1 | 1998 | 234 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 361 | 0.030 |
Why?
|
| Aftercare | 1 | 2018 | 252 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 2172 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 3523 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 1512 | 0.030 |
Why?
|
| Protective Factors | 1 | 2016 | 103 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1400 | 0.030 |
Why?
|
| Models, Biological | 2 | 2011 | 3187 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 14832 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2016 | 153 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1081 | 0.030 |
Why?
|
| Subtraction Technique | 1 | 2015 | 143 | 0.030 |
Why?
|
| Mice | 6 | 2015 | 35465 | 0.030 |
Why?
|
| Pattern Recognition, Automated | 1 | 2015 | 120 | 0.030 |
Why?
|
| Thyroxine | 1 | 2015 | 114 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 1994 | 100 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 703 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 1095 | 0.030 |
Why?
|
| Hematocrit | 1 | 1994 | 151 | 0.030 |
Why?
|
| Morbidity | 1 | 1995 | 399 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 689 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 142 | 0.030 |
Why?
|
| Mastectomy | 1 | 2000 | 1553 | 0.030 |
Why?
|
| Troponin I | 1 | 2014 | 130 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 1130 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 447 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 716 | 0.030 |
Why?
|
| Meditation | 1 | 2014 | 77 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2015 | 207 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2018 | 822 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 1995 | 477 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 2012 | 38 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 5405 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2013 | 347 | 0.030 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 327 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 5250 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 2015 | 431 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 318 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 5906 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 1994 | 309 | 0.020 |
Why?
|
| DNA Ligase ATP | 1 | 2011 | 53 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1047 | 0.020 |
Why?
|
| Animals | 6 | 2015 | 61714 | 0.020 |
Why?
|
| Cetuximab | 1 | 2013 | 474 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2011 | 82 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 398 | 0.020 |
Why?
|
| Feeding and Eating Disorders | 1 | 2012 | 91 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 367 | 0.020 |
Why?
|
| Pharyngitis | 1 | 2011 | 47 | 0.020 |
Why?
|
| Metformin | 1 | 2015 | 393 | 0.020 |
Why?
|
| Child | 3 | 2005 | 30466 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2011 | 126 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 748 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 704 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2353 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2003 | 3653 | 0.020 |
Why?
|
| Abdomen | 1 | 2012 | 349 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 353 | 0.020 |
Why?
|
| Defecation | 1 | 2010 | 57 | 0.020 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2009 | 31 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 2001 | 0.020 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 43 | 0.020 |
Why?
|
| Constipation | 1 | 2011 | 187 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1320 | 0.020 |
Why?
|
| Nephrectomy | 1 | 1994 | 796 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 398 | 0.020 |
Why?
|
| Gastrointestinal Motility | 1 | 2010 | 85 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 1330 | 0.020 |
Why?
|
| Skin | 1 | 2014 | 1270 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 1994 | 689 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2009 | 75 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2011 | 450 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 598 | 0.020 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2010 | 140 | 0.020 |
Why?
|
| Registries | 1 | 2015 | 2205 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 1498 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5138 | 0.020 |
Why?
|
| Motion | 1 | 2008 | 199 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 1255 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 726 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5309 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3939 | 0.020 |
Why?
|
| Asthma | 1 | 2015 | 894 | 0.020 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2006 | 64 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2006 | 43 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 682 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 1041 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2006 | 129 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 1570 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2006 | 105 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2011 | 5000 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 1061 | 0.020 |
Why?
|
| Hypertension | 1 | 2015 | 1583 | 0.020 |
Why?
|
| Critical Pathways | 1 | 2006 | 160 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 6204 | 0.020 |
Why?
|
| Pain, Postoperative | 1 | 2010 | 663 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2011 | 2231 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 489 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 5046 | 0.010 |
Why?
|
| Taxoids | 1 | 2006 | 1016 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2007 | 1318 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 3069 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 804 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 1552 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 1997 | 105 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 7632 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 1856 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3602 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3699 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2003 | 1713 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 6368 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 16987 | 0.010 |
Why?
|
| Apoptosis | 1 | 2003 | 7741 | 0.000 |
Why?
|